These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17318713)

  • 1. Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia.
    Paradowski B; Jaremko M; Dobosz T; Leszek J; Noga L
    J Neurol; 2007 Feb; 254(2):154-9. PubMed ID: 17318713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.
    Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H
    Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
    Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus.
    Lins H; Wichart I; Bancher C; Wallesch CW; Jellinger KA; Rösler N
    J Neural Transm (Vienna); 2004 Mar; 111(3):273-80. PubMed ID: 14991454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
    Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.
    Kapaki E; Paraskevas GP; Zalonis I; Zournas C
    Eur J Neurol; 2003 Mar; 10(2):119-28. PubMed ID: 12603286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau.
    Li G; Xiong K; Korff A; Pan C; Quinn JF; Galasko DR; Liu C; Montine TJ; Peskind ER; Zhang J
    J Alzheimers Dis; 2015; 47(4):883-7. PubMed ID: 26401768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.
    Sjögren M; Blomberg M; Jonsson M; Wahlund LO; Edman A; Lind K; Rosengren L; Blennow K; Wallin A
    J Neurosci Res; 2001 Nov; 66(3):510-6. PubMed ID: 11746370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
    Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
    Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.
    de Jong D; Jansen RW; Kremer BP; Verbeek MM
    J Gerontol A Biol Sci Med Sci; 2006 Jul; 61(7):755-8. PubMed ID: 16870640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.